At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
Atezolizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
In Brief
A Phase 2 clinical trial evaluating Atezolizumab, Bevacizumab, and 1 other intervention for Cervical Adenocarcinoma and 6 related conditions. Completed, enrolled 11 participants across 22 sites.
Detailed Summary
This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with cervical cancer that has come back, remains despite treatment, or has spread to other places in the body. Monoclonal antibodies, such as atezolizumab and bevacizumab, may shrink tumor cell and interfere with the ability of tumor cells to grow and spread.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma, Stage IV Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVB Cervical Cancer AJCC v6 and v7
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartMar 2017
Primary CompletionOct 2020
Study CompletionJan 2021
TodayJul 2026
First PostedOct 3, 2016
Enrollment StartMar 10, 2017
Primary CompletionOct 1, 2020
Study CompletionJan 13, 2021
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 9.7 years ago
Interventions
Atezolizumabdrug
Given IV
Bevacizumabbiological
Given IV
Laboratory Biomarker Analysisother
Correlative studies